Methotrexate Monotherapy for Unilateral Active Thyroid-Related Eye Disease
Ayman G. Elnahry1 M.D., Ph.D., Joseph H. Talbet2 B.A., Gehad A. Elnahry1M.D., Ph.D.
1Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt.
2 College of Medicine, Howard University, Washington, DC, USA.
Corresponding author, and correspondence to: Ayman G. Elnahry M.D., Ph.D., Department of Ophthalmology, Cairo University, Faculty of Medicine, Kasr Alainy street, Cairo, Egypt 11956. Phone: +20-1224927604. Fax: +20223682030. E-mail: ayman_elnahri@hotmail.com
Running title: Methotrexate for Active Thyroid Eye Disease
Ethical approval: This report was approved by Cairo University research ethics committee and followed the tenets of the Declaration of Helsinki
Financial support: None
Conflicts of Interest and Source of Funding: None
Keywords: Euthyroidism; Methotrexate; Monotherapy; Thyroid-related eye disease.
Key Clinical Message: Active thyroid-related eye disease may be safely and effectively managed using low-dose methotrexate monotherapy especially in patients intolerant to steroid therapy.